Clinical Gastroenterology最新文献

英文中文

IDDF2023-ABS-0231 The study of clinical characteristics and intestinal microbiota of pediatric clostridiodes difficile infection IDDF2023-ABS-0231儿童艰难梭菌感染临床特征及肠道菌群研究

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.208

Xiaolu Li, Yizhong Wang, Ting Zhang

引用次数: 0

IDDF2023-ABS-0284 Efficacy of probiotics pretreatment for intestinal preparation before colonoscopy in children with chronic constipation 慢性便秘儿童结肠镜检查前益生菌预处理肠道准备的疗效观察

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.216

Tong Li

引用次数: 0

IDDF2023-ABS-0181 Prevalence and risk factors for overweight among chinese adolescents 中国青少年超重患病率及危险因素

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.202

Junjie Huang, V. Keung, C. K. Cheung, A. S. Lo, S. Chan, W. Pang, L. W. Mui, Albert Lee, Martin C. S. Wong

引用次数: 0

IDDF2023-ABS-0141 The evolving role of technology in delivering patient-centric care in inflammatory bowel disease – an australasian experience using crohn’s colitis care e-health patient portal 技术在炎症性肠病中提供以患者为中心的护理中的不断发展的作用——澳大利亚使用克罗恩结肠炎护理电子卫生患者门户网站的经验

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.193

Jack McNamara, J. Pipicella, S. Connor, J. Andrews

引用次数: 0

IDDF2023-ABS-0016 The potential causal relationship between inflammatory bowel disease and cirrhosis in East Asian populations: a two-sample Mendelian randomization study 东亚人群炎症性肠病和肝硬化之间的潜在因果关系:一项双样本孟德尔随机化研究

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.161

Y. Deng, M. Wong

引用次数: 0

IDDF2023-ABS-0288 Diagnostic value of fecal PE-1 test in pancreatic exocrine insufficiency IDDF2023-ABS-0288粪便PE-1试验对胰腺外分泌不全的诊断价值

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.217

Manping Li, Hao Wu, Wen‐Bin Zou, Z. Liao, Zhaoshen Li

引用次数: 0

IDDF2023-ABS-0160 Fecal microbiota transplantation in patients with mild to moderate ulcerative colitis is associated with early clinical response in a real-world setting 在现实世界中，轻至中度溃疡性结肠炎患者的粪便微生物群移植与早期临床反应相关

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.197

S. Virmani, B. Kante, S. Vuyyuru, Peeyush Kumar, M. Singh, G. Makharia, S. Kedia, V. Ahuja

引用次数: 0

IDDF2023-ABS-0012 Gastrointestinal cancers are the leading cause of young onset cancer in the United States 胃肠道癌症是美国年轻发病癌症的主要原因

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.159

Benjamin Koh, Darren Jun-Hao Tan, Cheng-Han Ng, Wen-Hui Lim, Rebecca Wenling Zeng, Clarissa Elysia Fu, Jieling Xiao, Jia-Hong Koh, Benjamin Nah, Nicholas Syn, Margaret Teng, Ken Liu, Tamaki Nobuharu, Mark Muthiah, Chong-choon Seng, Vincent L Chen, Khay Guan Yeoh, Rohit Loomba

Background

Emerging data suggest that the incidence of young-onset cancers, defined as cancer diagnosed in adults < 50 years, is increasing, but has not been systematically assessed. We aimed to evaluate temporal changes in the incidence of young-onset cancers in a large, nationwide cohort study.

Methods

We analyzed data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results 17 registry from 2000 to 2019. Age-standardised incidence rates (ASIR) per 100,000 from 2010 to 2019 were extracted for young-onset cancers based on ICD-O-3 definitions, with rates age-adjusted to the United States standard population. The annual percentage change (APC) of the ASIRs were estimated via the SEER*Stat program.

Results

Between 2010 and 2019, a total of 562,145 cases of early-onset cancer (62.5% female) were recorded (IDDF2023-ABS-0012 Table 1). A total of 425,718 cases (75.7%) were White, 62,780 (11.2%) were Black, 55,976 (10.0%) were Asian or Pacific Islander individuals, 5120 (0.9%) were American Indian/Alaska Native and 12,551 (2.2%) were of unknown race. From 2010 to 2019, the annual percentage change of early-onset cancer was +0.276%, 95% CI 0.085 to 0.467%, p = 0.01(IDDF2023-ABS-0012 Table 2). There was lower APC in males vs females, -0.366 vs +0.667, p < 0.001. The APC in Whites, Blacks, Asians or Pacific Islanders, American Indian/Alaska Natives, and unknown races were +0.173, -0.637, +0.990, +1.170 and undefined, respectively. Gastrointestinal cancers were the fastest-growing cause of young-onset cancer (APC 2.161%, 95% CI: 1.660 - 2.665%), followed by urinary tract cancers (APC 1.336%, 95% CI: 0.607 – 2.070%), and breast cancers (APC 0.906%, 95% CI: 0.554 - 1.259%). Among gastrointestinal cancers, miscellaneous digestive organ cancers had the highest APC from 2010 to 2019 (APC 12.19%, 95% CI 9.99-14.43%), followed by cancers of the small intestine (APC 2.107%), stomach (APC 1.595%), and transverse colon (APC 1.689%).

Conclusions

The incidence of young-onset cancers is increasing in the United States. In particular, the incidence of the young-onset appendix, intrahepatic bile duct, and miscellaneous digestive organ cancers are rapidly rising. These data have important implications for surveillance strategies.

背景:新出现的数据表明，年轻发病的癌症(定义为在成人中诊断出的癌症)的发病率;50年来，正在增加，但尚未得到系统评估。我们的目的是在一项全国性的大型队列研究中评估年轻发病癌症发病率的时间变化。方法:我们分析了2000年至2019年美国国家癌症研究所监测、流行病学和最终结果17登记处的数据。根据ICD-O-3定义提取了2010年至2019年每10万人的年龄标准化发病率(ASIR)，并根据美国标准人群进行了年龄调整。asir的年百分比变化(APC)是通过SEER*Stat程序估计的。2010年至2019年期间，共记录了562,145例早发性癌症(62.5%为女性)(IDDF2023-ABS-0012表1)。共有425,718例(75.7%)为白人，62,780例(11.2%)为黑人，55,976例(10.0%)为亚洲或太平洋岛民，5120例(0.9%)为美洲印第安人/阿拉斯加原住民，12,551例(2.2%)为未知种族。2010 - 2019年，早发癌年变化百分比为+0.276%，95% CI 0.085 ~ 0.467, p = 0.01(IDDF2023-ABS-0012表2)。男性APC低于女性，为-0.366 vs +0.667, p <0.001. 白人、黑人、亚洲人或太平洋岛民、美洲印第安人/阿拉斯加原住民和未知种族的APC分别为+0.173、-0.637、+0.990、+1.170和未定义。胃肠道癌症是年轻发病癌症中增长最快的原因(APC为2.161%，95% CI为1.660 ~ 2.665%)，其次是泌尿道癌症(APC为1.336%，95% CI为0.607 ~ 2.070%)和乳腺癌(APC为0.906%，95% CI为0.554 ~ 1.259%)。2010 - 2019年胃肠道肿瘤中，消化器官杂类肿瘤的APC最高(APC 12.19%， 95% CI 9.99-14.43%)，其次是小肠(APC 2.107%)、胃(APC 1.595%)和横结肠(APC 1.689%)。结论:在美国，年轻发病的癌症发病率正在上升。特别是，年轻发病的阑尾、肝内胆管和各种消化器官癌症的发病率正在迅速上升。这些数据对监测战略具有重要意义。

{"title":"IDDF2023-ABS-0012 Gastrointestinal cancers are the leading cause of young onset cancer in the United States","authors":"Benjamin Koh, Darren Jun-Hao Tan, Cheng-Han Ng, Wen-Hui Lim, Rebecca Wenling Zeng, Clarissa Elysia Fu, Jieling Xiao, Jia-Hong Koh, Benjamin Nah, Nicholas Syn, Margaret Teng, Ken Liu, Tamaki Nobuharu, Mark Muthiah, Chong-choon Seng, Vincent L Chen, Khay Guan Yeoh, Rohit Loomba","doi":"10.1136/gutjnl-2023-iddf.159","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.159","url":null,"abstract":"<h3>Background</h3> Emerging data suggest that the incidence of young-onset cancers, defined as cancer diagnosed in adults < 50 years, is increasing, but has not been systematically assessed. We aimed to evaluate temporal changes in the incidence of young-onset cancers in a large, nationwide cohort study. <h3>Methods</h3> We analyzed data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results 17 registry from 2000 to 2019. Age-standardised incidence rates (ASIR) per 100,000 from 2010 to 2019 were extracted for young-onset cancers based on ICD-O-3 definitions, with rates age-adjusted to the United States standard population. The annual percentage change (APC) of the ASIRs were estimated via the SEER*Stat program. <h3>Results</h3> Between 2010 and 2019, a total of 562,145 cases of early-onset cancer (62.5% female) were recorded (IDDF2023-ABS-0012 Table 1). A total of 425,718 cases (75.7%) were White, 62,780 (11.2%) were Black, 55,976 (10.0%) were Asian or Pacific Islander individuals, 5120 (0.9%) were American Indian/Alaska Native and 12,551 (2.2%) were of unknown race. From 2010 to 2019, the annual percentage change of early-onset cancer was +0.276%, 95% CI 0.085 to 0.467%, p = 0.01(IDDF2023-ABS-0012 Table 2). There was lower APC in males vs females, -0.366 vs +0.667, p < 0.001. The APC in Whites, Blacks, Asians or Pacific Islanders, American Indian/Alaska Natives, and unknown races were +0.173, -0.637, +0.990, +1.170 and undefined, respectively. Gastrointestinal cancers were the fastest-growing cause of young-onset cancer (APC 2.161%, 95% CI: 1.660 - 2.665%), followed by urinary tract cancers (APC 1.336%, 95% CI: 0.607 – 2.070%), and breast cancers (APC 0.906%, 95% CI: 0.554 - 1.259%). Among gastrointestinal cancers, miscellaneous digestive organ cancers had the highest APC from 2010 to 2019 (APC 12.19%, 95% CI 9.99-14.43%), followed by cancers of the small intestine (APC 2.107%), stomach (APC 1.595%), and transverse colon (APC 1.689%). <h3>Conclusions</h3> The incidence of young-onset cancers is increasing in the United States. In particular, the incidence of the young-onset appendix, intrahepatic bile duct, and miscellaneous digestive organ cancers are rapidly rising. These data have important implications for surveillance strategies.","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136027395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IDDF2023-ABS-0222 Endoscopic ultrasound eus-s guided splenic lesion biopsy; noninvasive modality as an alternative to splenectomy IDDF2023-ABS-0222超声内镜引导下脾病变活检;无创方式作为脾切除术的替代方法

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.206

A. Urrehman, Aneel Madhwani, F. Ismail, O. Prakash, Z. Abbas, Zeeshan Uddin

引用次数: 0

IDDF2023-ABS-0173 Towards a new paradigm for the diagnostic of irritable bowel syndrome: a case study of the use of the raid-dx test 迈向肠易激综合征诊断的新范式:使用raid-dx测试的案例研究

Clinical Gastroenterology

Pub Date : 2023-06-01 DOI: 10.1136/gutjnl-2023-iddf.200

Josep Oriol Miquel-Cusachs, Marc Albert Carrasco, Leyanira Torrealba, Esther Fort Martorell, David Busquets Casals, Javier Pamplona Portero, Miriam Sabat Mir

Background

Retrospective review of the use of RAID-Dx, a test for the positive diagnosis of irritable bowel syndrome (IBS) through a faecal microbial signature. Data are presented by the Gastroenterology Department at the Hospital Universitari de Girona Dr. Josep Trueta – Institut d’Assistència Sanitària in the Girona area (Spain).

Methods

Observational, retrospective study with patients that meet ROME III/IV criteria for IBS who undergo the RAID-Dx test. A total of 34 patients were included (40.5±14.7 years, 60% women).

Results

The suspected diagnosis consisted of 7 IBS-diarrheal (20.6%), 12 IBS-mixed (35.3%), 4 IBS-constipation (11.8%), 5 IBS-undefined (14.7%), 3 IBS-post diverticulitis (8.9%), 1 dyspepsia (2.9%), and 1 with gastroesophageal reflux (2.9%). The RAID-Dx results showed that 58.8% of the patients presented a diagnosis compatible with IBS. 76.5% of patients showed some altered markers; the most affected was E. coli (44.1%), followed by A. muciniphila (32.4%). The results allowed to confirm the initial diagnostic suspicion in 67.7% of the cases, and a different diagnosis was reached in 81.1% of the remaining. Thus, the RAID-Dx assisted 94.1% of the diagnoses. Once the test was performed, 70.6% did not require additional diagnostic tests, starting treatment in 94.1% of cases. Treatments for patients diagnosed with IBS included I3.1 (30.3%), Bifibran (soluble fibre) (15.2%), compared with 17.4% I3.1, 30.4% Spiraxin, and 17.4% received a specific diet when obtained an incompatible diagnosis. Throughout the study, clinical improvement was observed after treatment in 76.5% of cases (52.9% total, 23.5% partial), of which 81.8% had obtained a positive diagnosis for IBS. On average, 78% of patients had received more than 4 visits before their referral to specialist care, specifically 5.7 visits for the group not compatible with IBS and doubling to 11.7 visits in patients with IBS. After performing the test, 87.5% of the patients had between 1 and 3 visits until hospital discharge.

Conclusions

The use of RAID-Dx could optimize the diagnosis of IBS and rationalize the use of healthcare resources by avoiding additional tests, shortening the time of diagnosis, and accelerating access to appropriate treatment.

背景回顾性回顾RAID-Dx的使用，这是一种通过粪便微生物特征来诊断肠易激综合征(IBS)的检测方法。数据由赫罗纳大学医院消化内科Josep Trueta博士-赫罗纳地区(西班牙)的Institut d ' assistncia Sanitària提供。方法观察性、回顾性研究符合ROME III/IV标准的IBS患者进行RAID-Dx测试。共纳入34例患者(40.5±14.7岁，60%为女性)。结果疑似ibs -腹泻7例(20.6%)，ibs -混合型12例(35.3%)，ibs -便秘4例(11.8%)，ibs -未明确型5例(14.7%)，ibs -憩室炎后3例(8.9%)，消化不良1例(2.9%)，胃食管反流1例(2.9%)。RAID-Dx结果显示，58.8%的患者诊断符合IBS。76.5%的患者出现一些标志物改变;感染最多的是大肠杆菌(44.1%)，其次是嗜粘杆菌(32.4%)。结果证实了67.7%的病例的初步诊断怀疑，81.1%的病例达到了不同的诊断。因此，RAID-Dx辅助诊断率为94.1%。一旦进行检测，70.6%的病例不需要额外的诊断检测，94.1%的病例开始治疗。诊断为IBS的患者的治疗包括I3.1(30.3%)、Bifibran(可溶性纤维)(15.2%)，而I3.1、30.4%的Spiraxin和17.4%的患者在诊断不相容时接受特定饮食。在整个研究中，76.5%的病例(52.9%的总病例，23.5%的部分病例)治疗后临床改善，其中81.8%的病例诊断为IBS阳性。平均而言，78%的患者在转诊到专科护理之前接受了4次以上的就诊，特别是不符合IBS的患者接受了5.7次就诊，IBS患者的就诊次数翻了一番，达到11.7次。在进行测试后，87.5%的患者在出院前进行了1至3次就诊。结论使用RAID-Dx可避免额外检查，缩短诊断时间，加快获得适当治疗，从而优化IBS的诊断，合理利用医疗资源。

{"title":"IDDF2023-ABS-0173 Towards a new paradigm for the diagnostic of irritable bowel syndrome: a case study of the use of the raid-dx test","authors":"Josep Oriol Miquel-Cusachs, Marc Albert Carrasco, Leyanira Torrealba, Esther Fort Martorell, David Busquets Casals, Javier Pamplona Portero, Miriam Sabat Mir","doi":"10.1136/gutjnl-2023-iddf.200","DOIUrl":"https://doi.org/10.1136/gutjnl-2023-iddf.200","url":null,"abstract":"<h3>Background</h3> Retrospective review of the use of RAID-Dx, a test for the positive diagnosis of irritable bowel syndrome (IBS) through a faecal microbial signature. Data are presented by the Gastroenterology Department at the <i>Hospital Universitari de Girona Dr. Josep Trueta – Institut d’Assistència Sanitària</i> in the Girona area (Spain). <h3>Methods</h3> Observational, retrospective study with patients that meet ROME III/IV criteria for IBS who undergo the RAID-Dx test. A total of 34 patients were included (40.5±14.7 years, 60% women). <h3>Results</h3> The suspected diagnosis consisted of 7 IBS-diarrheal (20.6%), 12 IBS-mixed (35.3%), 4 IBS-constipation (11.8%), 5 IBS-undefined (14.7%), 3 IBS-post diverticulitis (8.9%), 1 dyspepsia (2.9%), and 1 with gastroesophageal reflux (2.9%). The RAID-Dx results showed that 58.8% of the patients presented a diagnosis compatible with IBS. 76.5% of patients showed some altered markers; the most affected was <i>E. coli</i> (44.1%), followed by <i>A. muciniphila</i> (32.4%). The results allowed to confirm the initial diagnostic suspicion in 67.7% of the cases, and a different diagnosis was reached in 81.1% of the remaining. Thus, the RAID-Dx assisted 94.1% of the diagnoses. Once the test was performed, 70.6% did not require additional diagnostic tests, starting treatment in 94.1% of cases. Treatments for patients diagnosed with IBS included I3.1 (30.3%), Bifibran (soluble fibre) (15.2%), compared with 17.4% I3.1, 30.4% Spiraxin, and 17.4% received a specific diet when obtained an incompatible diagnosis. Throughout the study, clinical improvement was observed after treatment in 76.5% of cases (52.9% total, 23.5% partial), of which 81.8% had obtained a positive diagnosis for IBS. On average, 78% of patients had received more than 4 visits before their referral to specialist care, specifically 5.7 visits for the group not compatible with IBS and doubling to 11.7 visits in patients with IBS. After performing the test, 87.5% of the patients had between 1 and 3 visits until hospital discharge. <h3>Conclusions</h3> The use of RAID-Dx could optimize the diagnosis of IBS and rationalize the use of healthcare resources by avoiding additional tests, shortening the time of diagnosis, and accelerating access to appropriate treatment.","PeriodicalId":10401,"journal":{"name":"Clinical Gastroenterology","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136027399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical Gastroenterology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀